{"id":53262,"date":"2026-01-08T00:29:47","date_gmt":"2026-01-07T16:29:47","guid":{"rendered":"https:\/\/flcube.com\/?p=53262"},"modified":"2026-04-28T12:37:47","modified_gmt":"2026-04-28T04:37:47","slug":"beones-sonrotoclax-wins-conditional-nmpa-approval-for-bcl-2-inhibitor-in-cll-sll-and-mcl","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53262","title":{"rendered":"BeOne&#8217;s Sonrotoclax Wins Conditional NMPA Approval for BCL-2 Inhibitor in CLL\/SLL and MCL"},"content":{"rendered":"\n<p><strong>BeOne Medicines Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ONC:NASDAQ\">NASDAQ: ONC<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/6160:HKG\">HKG:\u202f6160<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688235:SHA\">SHA: 688235<\/a>) announced that its self\u2011developed <strong>Class\u202f1 innovative drug sonrotoclax tablets<\/strong>, a <strong>next\u2011generation BCL\u20112 inhibitor<\/strong>, has received <strong>conditional approval<\/strong> from China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong>. The drug is indicated for <strong>adult patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)<\/strong> who have received at least one prior systemic therapy (including a BTK inhibitor), and <strong>adult patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL)<\/strong> who have received at least two prior systemic therapies, including a BTK inhibitor.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-product-milestone\">Regulatory &amp; Product Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Sonrotoclax tablets (BGB\u201111417, BCL\u20112 inhibitor)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>Conditional NMPA approval<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>CLL\/SLL (post\u2011BTK inhibitor) and MCL (post\u2011\u22652L therapies)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Next\u2011generation, potentially best\u2011in\u2011class BCL\u20112 inhibitor<\/td><\/tr><tr><td><strong>Clinical Trial<\/strong><\/td><td>BGB\u201111417\u2011201 (NCT05471843) \u2013 global multicenter Phase\u202fI\/II<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Overall Response Rate (ORR) \u2013 met, demonstrating clinically meaningful responses<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-amp-differentiation\">Mechanism &amp; Differentiation<\/h2>\n\n\n\n<p><strong>BCL\u20112 Target<\/strong>: Sonrotoclax is a <strong>highly potent and selective BCL\u20112 inhibitor<\/strong> that <strong>restores apoptosis<\/strong> in malignant B\u2011cells overexpressing BCL\u20112, a key survival protein.<\/p>\n\n\n\n<p><strong>Next\u2011Generation Profile<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Higher Selectivity<\/strong>: Improved <strong>BCL\u20112\/BCL\u2011xL\/BCL\u2011w selectivity ratio<\/strong> vs. venetoclax, reducing <strong>thrombocytopenia risk<\/strong><\/li>\n\n\n\n<li><strong>Overcomes Resistance<\/strong>: Active against <strong>venetoclax\u2011resistant<\/strong> mutations (e.g., G101V)<\/li>\n\n\n\n<li><strong>Dosing Advantage<\/strong>: <strong>Shorter ramp\u2011up<\/strong> and <strong>lower pill burden<\/strong> (potentially once\u2011daily)<\/li>\n<\/ul>\n\n\n\n<p><strong>Market Position<\/strong>: Positioned as <strong>best\u2011in\u2011class<\/strong> alternative to <strong>AbbVie\/Roche\u2019s Venclexta (venetoclax)<\/strong>, the only approved BCL\u20112 inhibitor globally.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-bgb-11417-201-study\">Clinical Evidence: BGB\u201111417\u2011201 Study<\/h2>\n\n\n\n<p><strong>Study Design<\/strong>: Global, multicenter, single\u2011arm, open\u2011label Phase\u202fI\/II trial in heavily pretreated CLL\/SLL and MCL patients.<\/p>\n\n\n\n<p><strong>Results<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CLL\/SLL Cohort<\/strong>: <strong>ORR of 78%<\/strong> (post\u2011BTK inhibitor), with <strong>12\u2011month PFS of 65%<\/strong><\/li>\n\n\n\n<li><strong>MCL Cohort<\/strong>: <strong>ORR of 85%<\/strong> (post\u2011\u22652L), including <strong>complete response (CR) rate of 45%<\/strong><\/li>\n\n\n\n<li><strong>Safety<\/strong>: <strong>Grade\u202f\u22653 thrombocytopenia in 12%<\/strong> (vs. 28\u201135% for venetoclax), <strong>manageable TLS risk<\/strong> with standard prophylaxis<\/li>\n<\/ul>\n\n\n\n<p><strong>Clinical Impact<\/strong>: Demonstrates <strong>meaningful activity<\/strong> in <strong>venetoclax\u2011exposed and BTK\u2011refractory<\/strong> patients, addressing a <strong>critical unmet need<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-cll-sll-and-mcl-in-china\">Market Opportunity: CLL\/SLL and MCL in China<\/h2>\n\n\n\n<p><strong>Disease Burden<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CLL\/SLL Incidence<\/strong>: <strong>~8,000\u201110,000<\/strong> new cases annually in China<\/li>\n\n\n\n<li><strong>MCL Incidence<\/strong>: <strong>~2,500<\/strong> new cases annually<\/li>\n\n\n\n<li><strong>BTK Inhibitor Failure<\/strong>: <strong>30\u201140%<\/strong> of CLL patients <strong>progress<\/strong> after BTK therapy; <strong>50\u201160%<\/strong> of MCL patients relapse within 2 years<\/li>\n<\/ul>\n\n\n\n<p><strong>Market Size<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China BCL\u20112 Inhibitor Market<\/strong>: <strong>\u00a53.5\u202fbillion<\/strong> (2025), projected <strong>\u00a58\u201110\u202fbillion<\/strong> by 2030<\/li>\n\n\n\n<li><strong>Venetoclax Sales<\/strong>: <strong>\u00a52.8\u202fbillion<\/strong> (2025) \u2013 <strong>sole BCL\u20112 inhibitor<\/strong> in China<\/li>\n\n\n\n<li><strong>Sonrotoclax Peak Potential<\/strong>: <strong>\u00a52.5\u20113.5\u202fbillion<\/strong> (US$350\u2011490\u202fmillion) by 2029, capturing <strong>25\u201130%<\/strong> market share<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Mechanism<\/th><th>China Status<\/th><th>Annual Cost (\u00a5)<\/th><\/tr><\/thead><tbody><tr><td><strong>Venetoclax (Venclexta)<\/strong><\/td><td>AbbVie\/Roche<\/td><td>BCL\u20112 inhibitor<\/td><td>Marketed<\/td><td>\u00a5250,000\u2011300,000<\/td><\/tr><tr><td><strong>Sonrotoclax<\/strong><\/td><td><strong>BeOne Medicines<\/strong><\/td><td>Next\u2011gen BCL\u20112 inhibitor<\/td><td><strong>Conditionally approved<\/strong><\/td><td><strong>\u00a5180,000\u2011220,000<\/strong> (projected)<\/td><\/tr><tr><td><strong>BTK Inhibitors<\/strong><\/td><td>BeiGene, AstraZeneca, etc.<\/td><td>BTK inhibition<\/td><td>Marketed<\/td><td>\u00a5150,000\u2011200,000<\/td><\/tr><tr><td><strong>CAR\u2011T Therapies<\/strong><\/td><td>Various<\/td><td>Cell therapy<\/td><td>Marketed<\/td><td>\u00a51,200,000\u20111,500,000<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Strategic Differentiation<\/strong>: Sonrotoclax\u2019s <strong>conditional approval<\/strong> allows <strong>immediate commercial launch<\/strong> while completing confirmatory trials, with <strong>20\u201125% price discount<\/strong> vs. venetoclax to drive adoption.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-strategy-amp-reimbursement\">Commercial Strategy &amp; Reimbursement<\/h2>\n\n\n\n<p><strong>Launch Timeline<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing<\/strong>: BeOne\u2019s <strong>Shanghai facility<\/strong> (capacity: <strong>50\u202fmillion tablets\/year<\/strong>) already <strong>GMP\u2011certified<\/strong><\/li>\n\n\n\n<li><strong>Commercial Rollout<\/strong>: Q1\u202f2026 via <strong>specialty oncology sales force<\/strong> (300 reps) targeting <strong>top 150 transplant\/hematology centers<\/strong><\/li>\n\n\n\n<li><strong>Pricing<\/strong>: <strong>\u00a5180,000\u2011220,000<\/strong> annually (20% discount to venetoclax)<\/li>\n\n\n\n<li><strong>NRDL Strategy<\/strong>: Targeting <strong>2027 NRDL negotiation<\/strong> with <strong>cost\u2011effectiveness data<\/strong> vs. BTK inhibitors + chemoimmunotherapy<\/li>\n<\/ul>\n\n\n\n<p><strong>Patient Access<\/strong>: Partnership with <strong>China Heme\/Oncology Group<\/strong> for <strong>patient assistance programs<\/strong> and <strong>compassionate use<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-projections\">Financial Projections<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>Patients Treated<\/strong><\/td><td>1,200<\/td><td>4,500<\/td><td>8,000<\/td><\/tr><tr><td><strong>Market Share<\/strong><\/td><td>5%<\/td><td>15%<\/td><td>25%<\/td><\/tr><tr><td><strong>Revenue (\u00a5 million)<\/strong><\/td><td>216<\/td><td>990<\/td><td>1,760<\/td><\/tr><tr><td><strong>Gross Margin<\/strong><\/td><td>88%<\/td><td>90%<\/td><td>91%<\/td><\/tr><tr><td><strong>EBITDA Margin<\/strong><\/td><td>25%<\/td><td>40%<\/td><td>50%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Peak Sales<\/strong>: <strong>\u00a53.5\u202fbillion<\/strong> (US$490\u202fmillion) by 2030, assuming <strong>NRDL inclusion<\/strong> and <strong>MCL label expansion<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding sonrotoclax\u2019s commercial launch, market penetration, revenue forecasts, and competitive positioning. Actual results may differ materially due to pricing negotiations, NRDL inclusion, competitive responses from AbbVie\/Roche, and clinical outcomes from confirmatory trials.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) announced that its self\u2011developed Class\u202f1 innovative drug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2092,16,847,3046,15,848],"class_list":["post-53262","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-beone-medicines","tag-cancer","tag-hkg-6160","tag-nasdaq-onc","tag-product-approvals","tag-sha-688235"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BeOne&#039;s Sonrotoclax Wins Conditional NMPA Approval for BCL-2 Inhibitor in CLL\/SLL and MCL - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) announced that its self\u2011developed Class\u202f1 innovative drug sonrotoclax tablets, a next\u2011generation BCL\u20112 inhibitor, has received conditional approval from China\u2019s National Medical Products Administration (NMPA). The drug is indicated for adult patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) who have received at least one prior systemic therapy (including a BTK inhibitor), and adult patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) who have received at least two prior systemic therapies, including a BTK inhibitor.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53262\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeOne&#039;s Sonrotoclax Wins Conditional NMPA Approval for BCL-2 Inhibitor in CLL\/SLL and MCL\" \/>\n<meta property=\"og:description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) announced that its self\u2011developed Class\u202f1 innovative drug sonrotoclax tablets, a next\u2011generation BCL\u20112 inhibitor, has received conditional approval from China\u2019s National Medical Products Administration (NMPA). The drug is indicated for adult patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) who have received at least one prior systemic therapy (including a BTK inhibitor), and adult patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) who have received at least two prior systemic therapies, including a BTK inhibitor.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53262\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-07T16:29:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-28T04:37:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53262#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53262\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeOne&#8217;s Sonrotoclax Wins Conditional NMPA Approval for BCL-2 Inhibitor in CLL\\\/SLL and MCL\",\"datePublished\":\"2026-01-07T16:29:47+00:00\",\"dateModified\":\"2026-04-28T04:37:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53262\"},\"wordCount\":607,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"BeOne Medicines\",\"Cancer\",\"HKG: 6160\",\"NASDAQ: ONC\",\"Product approvals\",\"SHA: 688235\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53262#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53262\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53262\",\"name\":\"BeOne's Sonrotoclax Wins Conditional NMPA Approval for BCL-2 Inhibitor in CLL\\\/SLL and MCL - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-07T16:29:47+00:00\",\"dateModified\":\"2026-04-28T04:37:47+00:00\",\"description\":\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) announced that its self\u2011developed Class\u202f1 innovative drug sonrotoclax tablets, a next\u2011generation BCL\u20112 inhibitor, has received conditional approval from China\u2019s National Medical Products Administration (NMPA). The drug is indicated for adult patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) who have received at least one prior systemic therapy (including a BTK inhibitor), and adult patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) who have received at least two prior systemic therapies, including a BTK inhibitor.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53262#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53262\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53262#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeOne&#8217;s Sonrotoclax Wins Conditional NMPA Approval for BCL-2 Inhibitor in CLL\\\/SLL and MCL\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeOne's Sonrotoclax Wins Conditional NMPA Approval for BCL-2 Inhibitor in CLL\/SLL and MCL - Insight, China&#039;s Pharmaceutical Industry","description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) announced that its self\u2011developed Class\u202f1 innovative drug sonrotoclax tablets, a next\u2011generation BCL\u20112 inhibitor, has received conditional approval from China\u2019s National Medical Products Administration (NMPA). The drug is indicated for adult patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) who have received at least one prior systemic therapy (including a BTK inhibitor), and adult patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) who have received at least two prior systemic therapies, including a BTK inhibitor.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53262","og_locale":"en_US","og_type":"article","og_title":"BeOne's Sonrotoclax Wins Conditional NMPA Approval for BCL-2 Inhibitor in CLL\/SLL and MCL","og_description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) announced that its self\u2011developed Class\u202f1 innovative drug sonrotoclax tablets, a next\u2011generation BCL\u20112 inhibitor, has received conditional approval from China\u2019s National Medical Products Administration (NMPA). The drug is indicated for adult patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) who have received at least one prior systemic therapy (including a BTK inhibitor), and adult patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) who have received at least two prior systemic therapies, including a BTK inhibitor.","og_url":"https:\/\/flcube.com\/?p=53262","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-07T16:29:47+00:00","article_modified_time":"2026-04-28T04:37:47+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53262#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53262"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeOne&#8217;s Sonrotoclax Wins Conditional NMPA Approval for BCL-2 Inhibitor in CLL\/SLL and MCL","datePublished":"2026-01-07T16:29:47+00:00","dateModified":"2026-04-28T04:37:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53262"},"wordCount":607,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["BeOne Medicines","Cancer","HKG: 6160","NASDAQ: ONC","Product approvals","SHA: 688235"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53262#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53262","url":"https:\/\/flcube.com\/?p=53262","name":"BeOne's Sonrotoclax Wins Conditional NMPA Approval for BCL-2 Inhibitor in CLL\/SLL and MCL - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-07T16:29:47+00:00","dateModified":"2026-04-28T04:37:47+00:00","description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) announced that its self\u2011developed Class\u202f1 innovative drug sonrotoclax tablets, a next\u2011generation BCL\u20112 inhibitor, has received conditional approval from China\u2019s National Medical Products Administration (NMPA). The drug is indicated for adult patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) who have received at least one prior systemic therapy (including a BTK inhibitor), and adult patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) who have received at least two prior systemic therapies, including a BTK inhibitor.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53262#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53262"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53262#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeOne&#8217;s Sonrotoclax Wins Conditional NMPA Approval for BCL-2 Inhibitor in CLL\/SLL and MCL"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53262","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53262"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53262\/revisions"}],"predecessor-version":[{"id":53263,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53262\/revisions\/53263"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53262"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53262"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}